Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema

scientific article

Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.OPHTHA.2013.09.023
P932PMC publication ID3946576
P698PubMed publication ID24332536
P5875ResearchGate publication ID259509824

P50authorDouglas JabsQ5301649
Jennifer ThorneQ61877550
John H KempenQ63819726
Robert B. NussenblattQ83234942
Grace A Levy-ClarkeQ83235015
Systemic Immunosuppressive Therapy for Eye Diseases Cohort StudyQ83235469
P2093author name stringC Stephen Foster
Ebenezer Daniel
Eric B Suhler
James T Rosenbaum
Marc H Levin
Maxwell Pistilli
Sapna S Gangaputra
P2860cites workStandardization of uveitis nomenclature for reporting clinical data. Results of the First International WorkshopQ24727581
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort StudyQ33321092
Smoking as a risk factor for cystoid macular edema complicating intermediate uveitisQ33322621
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuityQ33360668
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort studyQ33478325
Hypopyon in patients with uveitisQ33518200
Cyclosporine for ocular inflammatory diseasesQ33520584
Cigarette smoking as a risk factor for uveitisQ33695558
Risk of relapse in primary acute anterior uveitisQ33934732
Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseasesQ34224273
Risk of hypotony in noninfectious uveitisQ34337589
Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomographyQ35570770
Adverse effects of smoking on patients with ocular inflammationQ35582576
Degree, duration, and causes of visual loss in uveitis.Q35592376
The impact of macular edema on visual function in intermediate, posterior, and panuveitis.Q36814725
Methotrexate for ocular inflammatory diseasesQ37204512
Causes and frequency of blindness in patients with intraocular inflammatory diseaseQ37319691
Azathioprine for ocular inflammatory diseasesQ37366679
Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography.Q46520542
Risk factors for the development of macular edema in noninfectious uveitis.Q51060569
Long-term visual outcome and complications associated with pars planitisQ58397008
Effect of lymphocytic infiltration on the blood-retinal barrier in experimental autoimmune uveoretinitisQ68158018
International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory diseaseQ69741243
Pathology of human cystoid macular edemaQ70574403
Role of the vitreous in the prognosis of peripheral uveitisQ72542156
Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edemaQ77156632
Risk factors for cystoid macular oedema in patients with uveitisQ79196584
Impact of macular edema on visual acuity in uveitisQ80023608
Course of macular edema in uveitis under medical treatmentQ80454666
Long-term follow-up of inflammatory cystoid macular edemaQ83823317
P433issue2
P921main subjectuveitisQ280027
visual impairmentQ737460
P304page(s)588-95.e1
P577publication date2013-12-12
P1433published inOphthalmologyQ7098109
P1476titleIncidence of visual improvement in uveitis cases with visual impairment caused by macular edema
P478volume121

Reverse relations

cites work (P2860)
Q90614897Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis
Q94333937Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis
Q35681664Clinical trials in noninfectious uveitis
Q92691394Cochrane corner: why we still don't know whether anti-TNF biologic therapies impact uveitic macular oedema
Q41592704Correlation between Visual Acuity, Inner Segment/Outer Segment Junction, and Cone Outer Segment Tips Line Integrity in Uveitic Macular Edema
Q37349073Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis
Q36310489Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial
Q90397147Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges
Q36218114Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results
Q61810687Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis
Q53107185Quantitative analysis of vitreous inflammation using optical coherence tomography in patients receiving sub-Tenon's triamcinolone acetonide for uveitic cystoid macular oedema.
Q40661330Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis.
Q38953088Structure-function Relationships in Uveitic Cystoid Macular Edema: Using En Face Optical Coherence Tomography to Predict Vision
Q28068067The effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocol
Q54641208[Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014].

Search more.